

Poster Presentation Program

Room F (1F Multi-purpose Hall)

Presentation(Odd number):November 17 (Tue.) 17:30-18:30

Presentation(Even number):November 18 (Wed.) 17:00-18:00

Presentation Number	Category	Presenter	Presentation Title
P-001	Absorption	Atsushi Hosomi	Utility of three-dimensional (3D) human skin models in assessing percutaneous absorption of diverse topical formulations
P-002		Ryosuke Negoro	Functional Characterization of Air-Liquid Interface-Cultured Caco-2 Cells for Intestinal Drug Absorption and Metabolism Models
P-003		Ilona Wehl	Establishment and characterization of air-liquid interface-cultured human intestinal organoid-derived monolayers as an in vitro platform for pharmacokinetic studies
P-004		Takako Sono	Development of a Modified Caco-2 Permeability Assay for Targeted Protein Degraders
P-005		Shun Uehara	Evaluation of the effects of the physicochemical properties of cell culture inserts on the functional properties of human iPS cell-derived intestinal organoid monolayers
P-006		Hisanao Kishimoto	Development of a mucus-intestinal cell membrane model using a novel Fluorinert FC-40-liquid interface (FLI) cell culture method
P-007	Others	Tatsuya Inui	Functional enhancement of human iPS cell-derived intestinal epithelial cells by optimizing ALI culture conditions
P-008	Absorption	Saya Akiyama	Development of Dissolution Evaluation System for Drug Absorption(VIII):IVIVC Studies on Gastric Emptying Gastrointestinal Stability, and Oral Peptide Formulations
P-009		Hayato Asai	Development of Dissolution Evaluation System for Drug Absorption(IX):Additional Transdermal Absorption Module for Nanoparticle Formulations
P-010		Naoyuki Tatsumi	Assessment of Common Marmosets (Callithrix jacchus) as a Tool for Predicting Human Oral Bioavailability
P-011		Yuki Ando	Review of commercially available subcutaneous antibody products: bridging strategies for device changes and the effects of injection conditions on drug absorption in humans
P-012		Naomi Yamakawa	ADME profiling of targeted oral peptide Icotrokinra
P-013		Fuyu Hayashi	Gastrointestinal absorption of salmon milt-derived oligodeoxyribonucleotides as dinucleotides in mice
P-014		Yui Oyabu	Nonparametric prediction of delayed-absorption plasma profiles of ODTs administered postprandially without water based on in vitro gastric emptying

Poster Presentation Program

Room F (1F Multi-purpose Hall)

Presentation(Odd number):November 17 (Tue.) 17:30-18:30

Presentation(Even number):November 18 (Wed.) 17:00-18:00

Presentation Number	Category	Presenter	Presentation Title
P-015	Absorption	HENGMIN TANG	Evaluation of Species Differences in P-Glycoprotein-Mediated Nonlinear Absorption Using Six Marketed Substrate Drugs
P-016		Yuko Tomonaga	Elucidation of physiological factors limiting colonic drug absorption using quantum dots-based Imaging
P-017		Hina Yamamoto	A predictive framework for osmolality-dependent food/beverage-drug interactions based on membrane permeability and permeation mechanisms
P-018	Regulation	Seigo Shuto	Intronic G-quadruplexes in the <i>ABCC2</i> gene suppress MRP2 expression and enhance cisplatin sensitivity in hepatoma cells
P-019		Tsutomu Sakuma	Regulation of sex-predominant expression of mouse <i>Cyp3a41</i> and <i>3a44</i> genes
P-020	AI/Bioinformatics /Omics	Lianjin Cai	Predicting Human Pharmacokinetics with AI and Machine Learning through Emerging Strategies in Drug Discovery
P-021		Takuya Suzuoka	Machine Learning with a Mass-Balance Constraint for Pharmacokinetic Parameter Prediction
P-022		Mamiko Imaoku	AI based metabolite prediction as an aid to MS-based metabolite identification, pharmacokinetics and tissue distribution for a PROTAC drug
P-023		Tsubasa Nagae	Auxiliary Assay-Boosted Machine Learning for Human PXR Induction Prediction: A 4th-Place Finish in the OpenADMET PXR Challenge
P-024		Soyoka Tanihata	Predicting the necessity of monkey data for human clearance prediction using chemical structure
P-025	Bioimaging/Bioanalysis	Eiko Suzuki	Challenges in measuring local tissue concentrations of biologics: estimation of epidermal drug concentrations using a combined ligand-binding assay and Quanticell® imaging approach
P-026		Ryuta Kobayashi	High-Efficiency Quantification of Nusinersen Using Streamlined Kit-Based Sample Preparation and LC-MS/MS
P-027		Etsuko Suzuki	Implementation of microscale chromatography for high sensitivity - high throughput quantification of GLP-1RAs pharmaceuticals in plasma
P-028		Kanae Kawai	Development of a Bioanalytical Method for Active Triphosphate Metabolites of Nucleoside Analogs Unstable in Biological Samples

Poster Presentation Program

Room F (1F Multi-purpose Hall)

Presentation(Odd number):November 17 (Tue.) 17:30-18:30

Presentation(Even number):November 18 (Wed.) 17:00-18:00

Presentation Number	Category	Presenter	Presentation Title
P-029	Bioimaging/Bioanalysis	Shogo Suga	Development of a workflow for mapping the brain distribution of administered drugs in the mouse brain
P-030		Motoji Oshikata	Evaluation of targeted and untargeted workflows by DESI MSI of novel photocleavable Mass-Tagged Antibodies to image biomarkers in tissues
P-031		Haruki Iida	Evaluation of the Disposition and Fetal Transfer of a Recombinant Aminopeptidase A-Fc Fusion Protein in Mice Using Complementary Analytical Methods
P-032	New Modalities	Kenta Haraya	Mitigating Anti-Drug Antibody Formation to Enable Accurate Pharmacokinetic Evaluation in Cynomolgus Monkeys Through Anti-CD40 Antibody Co-administration
P-033		Takahiro Kikuchi	Pharmacokinetic Evaluation of the Approved Drug Volanesorsen in Rats Using the Novel Nucleic Acid Labeling Method (FT-Labeling)
P-034		Sayaka Yoshida	Cell-based non-specific uptake assays to predict human pharmacokinetics of monoclonal antibodies and Fc-fusion proteins
P-035		Noriyasu Sano	Pharmacokinetic evaluation of TPDs: dosing vehicle effects on oral exposure and E3 ligase-dependent brain penetration
P-036		Hiroyuki Sato	Analysis of antibody permeability and transport mechanisms using a novel human iPSC-derived brain microvascular endothelial cell model
P-037		Tomoshige Ando	Structural analysis of peptide isomers by cyclic ion mobility mass spectrometry
P-038		Weilin Shen	Prediction of Human Pharmacokinetics of Beyond-rule-of-5 Targeted Protein Degraders from a Single Study in Chimeric Mice with Humanized Livers
P-039		Ayaka Hashimoto	Pharmacodynamics of cyclic dinucleotides in brain microvessel endothelial cells and leptomeningeal cells
P-040		Ami Hiraga	Effect of Fc γ receptor expression on cancer-associated myeloid cells on anti-CTLA-4 antibody binding in a peritoneal dissemination model
P-041	Drug-Drug Interactions	Motohiro Kato	Characterization of Intestinal CYP3A4 Inhibition Using Midazolam Drug-Drug Interaction Studies and Evaluation of the Predictive Performance of the Mechanistic Static PK Model
P-042		Yuki Matsumoto	Implementation and Regulatory Considerations for Organic Cation Transporter 1 Inhibition Assessment in New Molecular Entities Approved in Japan

Poster Presentation Program

Room F (1F Multi-purpose Hall)

Presentation(Odd number):November 17 (Tue.) 17:30-18:30

Presentation(Even number):November 18 (Wed.) 17:00-18:00

Presentation Number	Category	Presenter	Presentation Title
P-043	Drug-Drug Interactions	Ryotaro Iwakiri	Prediction of clinical drug-drug interactions based on in vitro CYP/UGT inhibition assessment and PK modeling for acotiamide
P-044		Asami Saito	Evaluation of criteria for OCT1-mediated DDI risk based on metformin-related adverse events
P-045		Shengyu Dai	Endoplasmic reticulum-localized organic anion transporter OAT2 mediates the zidovudine-probenecid interaction
P-046		Hiroaki Takubo	Endogenous biomarker-based quantitative prediction of CYP3A inhibition- and induction-mediated drug-drug interactions
P-047		Yuta Seki	Translational evaluation of pyridoxic acid (PDA) as an endogenous biomarker for OAT1/3-mediated DDI risk prediction using non-clinical animal models
P-048		Yasuhiro Masubuchi	Mechanism-based inhibition of CYP2D6 by levomepromazine, a phenothiazine antipsychotic agent
P-049		Shotaro Uehara	Evaluation of the Idelalisib-Midazolam Drug-Drug Interaction in Humanized-Liver Mice
P-050		Kokoha Okamoto	Population Pharmacokinetic-Pharmacodynamic Modeling of Warfarin-Sulfamethoxazole Interactions: Implementation for Model-informed Precision Dosing
P-051		Tomoyo Honda	Metabolic switching of quizartinib by efavirenz-mediated allosteric heteroactivation of CYP3A4
P-052	Others	Young-Won Chin	An integrated in vitro and in silico evaluation of cytochrome P450 (CYP) inhibition by mangostin-type xanthenes
P-053		Shota Ichimizu	Binding modes of amiodarone and desethylamiodarone to lipoproteins: A circular dichroism spectroscopic investigation
P-054	Transporters	Kenta Mizoi	Development of a system to evaluate biliary drug excretion using human cholangiocyte organoid monolayers
P-055		Takeru Ito	Mechanism of choline transport at the blood-testis barrier
P-056		Hiroki Sunakawa	Characterization of the distribution and urinary excretion of uric acid in global Mrp4 knock-out mice

Poster Presentation Program

Room F (1F Multi-purpose Hall)

Presentation(Odd number):November 17 (Tue.) 17:30-18:30

Presentation(Even number):November 18 (Wed.) 17:00-18:00

Presentation Number	Category	Presenter	Presentation Title
P-057	Transporters	Chihiro Yoden	Transport Characterization of N-Lactoylphenylalanine (Lac-Phe) in the intestinal cell line Caco-2 and the Skeletal Muscle Cell Line C2C12
P-058		Yuka Yaguchi	A clearance pathway of anionic and cationic compounds from the cerebrospinal fluid across the arachnoid mater in rats and monkeys
P-059		Yuma Tega	Influence of glioblastoma cells on breast cancer resistance protein function at the blood-brain barrier
P-060		Kokona Yamaguchi	Investigation of the Regulatory Mechanisms of Na ⁺ -Independent Neutral Amino Acid Transporters in the Skeletal Muscle Cell Line C2C12
P-061		Akito Takahashi	Optimization of assay conditions for evaluating transporter substrate properties of beyond-rule-of-five compounds
P-062		Yukari Kamikozawa	Evaluation of an In Vitro Monkey Blood-Brain Barrier(BBB) Kit for Predicting CNS Drug Distribution and Human Translation
P-063		Makoto Ozawa	Intracerebral distribution of drugs with diverse blood-brain barrier transport characteristics: In vivo analysis using brain microdialysis in cynomolgus monkeys
P-064		Kiysohi Oka	Involvement of cancer-type OATP1B3 in the cellular retention of nanvuranlat in human cholangiocarcinoma cells
P-065		Saki Noguchi	Identification of selective inhibitors for the human renal organic anion transporter OAT4 via drug library screening
P-066		RIO OGAWA	Functional characterization of an orphan transporter localized to the endoplasmic reticulum
P-067		Misato Kunieda	Investigation of the regulatory mechanisms of monocarboxylate transporter 7 expression
P-068		Yuki Matsui	Characterization of Skeletal Muscle Distribution of Ergothioneine, a Food-Derived Antioxidant
P-069		Shingo Ito	Diurnal variation in protein expression at the mouse blood-brain barrier using quantitative proteomics
P-070		Aoi Kato	Transport of fluorescein and 5-carboxyfluorescein by novel organic anion transporters in HK-2 cells

Poster Presentation Program

Room F (1F Multi-purpose Hall)

Presentation(Odd number):November 17 (Tue.) 17:30-18:30

Presentation(Even number):November 18 (Wed.) 17:00-18:00

Presentation Number	Category	Presenter	Presentation Title
P-071	Transporters	Mizuki Uchi	Changes in renal and hepatic proteome of creatine transporter deficient mice with oral creatine administration
P-072		Yukio Kato	PBPK model incorporating enterohepatic circulation of multi-kinase inhibitor regorafenib to describe prolonged exposure after oral administration
P-073	Others	Tomoe Komori	Prediction of Human Pharmacokinetics of Heterobifunctional Molecules Using Humanized Liver Chimeric Mice
P-074		Keita Yamanouchi	Non-invasive Evaluation of Enterohepatic Circulation in Preclinical Animals Using Cholestyramine
P-075		Saori Takahashi	Analysis of human blood-brain barrier permeability using $K_{s,uu,CSF}$ calculated from forensic cerebrospinal fluid and serum samples
P-076	Drug Delivery System	Ryohei Kuwahara	<i>In vitro</i> brain permeability characterization of SLS-engineered antibodies using human blood-brain barrier spheroid models
P-077		Masahiro Hashimoto	Process development and optimization of antibody-modified mRNA-LNPs
P-078		Hajime Eguchi	Development of Novel Ionizable Lipids for mRNA-LNPs
P-079		Shogo Yasuda	Intraperitoneal disposition and tumor distribution of polymer with different sizes and structures in a murine peritoneal metastasis model
P-080		Yuma Iguchi	Comparison of Intracellular Delivery Characteristics of Lipid Nanoparticles with Different Lipid Compositions across Cell Lines and Evaluation of Delivery to Peritoneal Metastases
P-081		Shoma Chikamatsu	Enhancement of Caco-2 barrier function by low bicarbonate-induced cellular remodeling
P-082		Daisuke Inoue	Establishment of cerebral microdialysis method to evaluate drug transport efficacy from nose to brain affected by cerebral fluid clearance
P-083		Kaede Yokoyama	Single-Cell Imaging Analysis of GalNAc-siRNA Dynamics and Target Gene Silencing
P-084	Drug Metabolism Enzymes	Yuko Shiota	Structural Characterization of dGSH and CysGlu-Dan Adducts by HPLC-FLR-HRMS/MS for Reactive Metabolite Assessment

Poster Presentation Program

Room F (1F Multi-purpose Hall)

Presentation(Odd number):November 17 (Tue.) 17:30-18:30

Presentation(Even number):November 18 (Wed.) 17:00-18:00

Presentation Number	Category	Presenter	Presentation Title
P-085	Drug Metabolism Enzymes	Rei Koyama	Why Is Human CYP4B1 Catalytically Silent? Ser427 Is Not Sufficient to Explain the Loss of Function
P-086		Genki Ushirozako	Correlation between CYP3A5 protein levels and midazolam 1'-hydroxylase activity in tree shrew liver
P-087		Yuu Miyauchi	Prediction of the roles of cysteine residues in UGT1A1 oligomerization based on analyses of UGT2B7 mutants and predicted structures
P-088		Miki Katoh	Regulation of UGT1A1 expression by β -catenin signaling in HepG2 cells
P-089		Ayaka Kojima	Kinetic characterization of 14,15-epoxyeicosatrienoic acid formation from arachidonic acid by human CYP2C9 genetic variants and CYP2C19
P-090		Daichi Sano	Development of a candidate selection workflow for mitigating AO-mediated metabolic risk in early drug discovery
P-091		Koji Tanaka	Metabolite profiling of ASP1570 in participants with advanced solid tumors and in vitro enzyme identification of major metabolites: insights into human metabolism of ASP1570
P-092		Masato Takahashi	Side-chain effects on solubility, chemical stability, and bioactivation of propofol ester prodrugs
P-093		Makiko Shimizu	Prediction of functional impairment in flavin-containing monooxygenase 3 (FMO3) variants using in silico binary classification model
P-094		Rei Asano	Functional characterization of human iPSC cell-derived hepatic organoids cultured in different basal media
P-095	Toxicity	Elif Oz	Photoactivated Xenobiotic Stress Induced by Quaternized Silicon Phthalocyanines in Breast Cancer Models
P-096	Others	Jiraporn Kuesap	In vitro screening of medicinal plant ethanolic extracts for antimalarial activity against Plasmodium falciparum and cytotoxicity assessment
P-097	Toxicity	Naoko Ohtsu	Early Risk Assessment of drug-Induced Bilirubin Elevation: Insights from Transporter and Enzyme Inhibition Studies.
P-098		Yukiko Ueyama-Toba	Development of a human iPSC-derived hepatic organoid platform for isoform-dependent evaluation of CYP3A function

Poster Presentation Program

Room F (1F Multi-purpose Hall)

Presentation(Odd number):November 17 (Tue.) 17:30-18:30

Presentation(Even number):November 18 (Wed.) 17:00-18:00

Presentation Number	Category	Presenter	Presentation Title
P-099	Toxicity	Yusei Uraya	Comparative evaluation of human iPS cell-derived intestinal organoid and Caco-2 cell for predicting drug-induced gastrointestinal toxicity
P-100		Yoshiki Hashimoto	A translational strategy for predicting drug-induced nausea and vomiting based on multi-donor analysis of human intestinal organoids
P-101		Wataru Ochiai	Maternal-Fetal Pharmacokinetics of Diazepam and Its Metabolites: Unexpected Placental Transfer of Oxazepam-Glucuronide in Pregnant Mice
P-102	Others	Srinuan Somroop	Antibacterial activity and antioxidant activity in Thai herbal extracts against Staphylococcus aureus
P-103		Nutnicha Suphakhonchuwong	Molecular Characterization of Permethrin Resistance in Head Lice among Primary School Children in Thailand
P-104	Systems Pharmacology/Pharmacometrics	Daisuke Aibara	A novel cytoskeleton–nuclear receptor axis controlling lipid metabolism: SPRR1A releases LXR α from β -actin
P-105		Kazuhiro Kobayashi	A translational PBPK model incorporating tumor TfR1 dynamics to inform first-in-human dose selection for the bispecific antibody KK2260
P-106		Keitaro Nakagawa	Translational Approach for Human Pharmacokinetic Prediction of Antibody-Drug Conjugate Using Human FcRn Transgenic Mouse
P-107		Fumiyoshi Yamashita	A fast and accurate covariate modeling approach using posterior summaries in population pharmacokinetics
P-108		Shiho Suruki	Integrated Thrombopoiesis-Based Model for Romiplostim PK/PD in Healthy Adults and Patients with Aplastic Anemia
P-109		Masatoshi Masuda	Exploratory Analysis of Hepatic UGT2B7 Expression in Patients with Hepatic Impairment Using a Physiologically Based Pharmacokinetic Model of Nalmefene
P-110		Koichi Handa	Exploring differences in allometric scaling exponents between rats and monkeys and humans of ages that are relevant in drug development
P-111		Toshiaki Tsuchitani	Individual-Level Target Occupancy Estimation of Telmisartan from Phase I Data Using a TMDD-PBPK Model

Poster Presentation Program

Room F (1F Multi-purpose Hall)

Presentation(Odd number):November 17 (Tue.) 17:30-18:30

Presentation(Even number):November 18 (Wed.) 17:00-18:00

Presentation Number	Category	Presenter	Presentation Title
P-112	Systems Pharmacology/Pharmacometrics	Satoshi Nakayama	A novel scaling approach for human pharmacokinetic prediction of antibody-drug conjugates using minimal nonclinical data: Integration of monkey PK and in vitro data
P-113		Takashi Yoshikado	Mechanistic PBPK modelling of linagliptin, a DPP-4 inhibitor, to capture its complex target-mediated drug disposition
P-114		Mai Ozaki	Renal biomarker-informed pharmacokinetic modeling for predicting plasma and tumor exposure during FOLFOX therapy in a CKD colorectal cancer rat model
P-115		Withdrawal of Presentation	
P-116	Pharmacogenetics/Biomarkers	Eiji Hishinuma	Structural and functional characterization of rare Japanese <i>DPYD</i> variants and their effects on DPD activity and homodimerization
P-117		Yui Iwamoto	PD-L1-positive extracellular vesicles as a pharmacodynamic biomarker for monitoring tumor immune activation targeted by the tumor-targeted CD40 agonist KK2269 in nonclinical models
P-118		Mana Yajima	Comprehensive Expression Analysis of Transporters and Their Associated Proteins in Liver Cancer
P-119		Yukari Tanaka	Quantitative spatial profiling of brain neurotransmitters using microwave fixation and imaging mass spectrometry
P-120		Yoichi Tanaka	Comparison of PBPK predictions of human blood concentrations across <i>cytochrome P450 2C9</i> genotypes using different <i>in vitro</i> methods for intrinsic clearance determination
P-121	Microphysiological Systems (Organs on a Chip)	Haruto Sakai	Engineering the Blood-Brain Barrier: Spatiotemporal Control of Network Formation with 3D Endothelial Spheroids
P-122		Fuki Yokoi	Organoid- and organ-on-a-chip-based drug screening for inflammatory bowel disease
P-123		Noriko Matsumoto	Image-Based Workflows for Permeability and Vascular Phenotyping in Microvascular MPS Models
P-124		Ai Ushiro	The evaluation of drug disposition functions under a physiological oxygen gradient using human iPS cell-derived intestinal organoid
P-125		Hanae Morio	Human immortalized cell-based blood-brain barrier models as a tool for evaluating BBB permeability and brain-cell transduction potential of AAV vectors